Athens, ALNCT06283966Now EnrollingIRB Ready

COPD Clinical Trial in Athens, AL

Access cutting-edge copd treatment through this phase 3 clinical trial at a research site in Athens. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Athens location

Preparing your pre-screening questions…

Expert Care in Athens

Access copd specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related copd treatment provided free

Apply for This Athens Location

Check if you qualify for this copd clinical trial in Athens, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Athens

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Athens site if eligible
  4. 4Begin participation

About This COPD Study in Athens

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Male or female participants must be 40 to 80 years of age inclusive, at the time of signing the ICF.
Demonstrate acceptable MDI administration technique at Visit 1 (V1) and Visit 2 (V2)
A diagnosis of COPD confirmed by a post-bronchodilator FEV1/FVC ratio \< 70% at V1.
Current or former smokers with a history of at least 10 pack-years of cigarette smoking; defined as (number of cigarettes per day/20) x number of years smoked. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to V1.
A baseline peripheral blood eosinophil count of ≥ 100 cells/mm3 assessed at Visit 1 by the central laboratory
A CAT score of ≥ 10 at Visit 1.
Participant must fulfill at least 1 of the 4 CV disease/risk factor criteria below \[(a), (b), (c), or (d)\]:
: Established CV Disease
: Combination of CV risk factors:
Hypertension
Diabetes Mellitus
Chronic Kidney Disease
Dyslipidemia
: High risk of CV disease determined using an established CV risk assessment tool.
: CT coronary Artery Calcification
Willing and, in the opinion of the investigator, able to adjust current COPD therapy, as required by the protocol.
Willing to visit at the study site or participate in virtual visits as required per the protocol to complete all study assessments.
A female is eligible to enter and participate in the study if the female is of:
Non-childbearing potential: either permanently sterilized or who are post-menopausal.
Childbearing potential: has a negative serum pregnancy test at V1 and must use one highly effective form of birth control.
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

Exclusion Criteria

Active diagnosis of asthma within the past 5 years (previous diagnosis as a child or adolescent are eligible), asthma-COPD overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension.
End-stage renal disease requiring renal replacement therapy
History of heart or lung transplant or actively listed for heart or lung transplant.
Implanted left ventricular assist device or implant anticipated in \< 3 months.
History of lung cancer and/or treatment for lung cancer within the 5 years prior to Visit 1.
Unstable or life-threatening cardiac disease - participants with any of the following at Visit 1 would be excluded:
An MI or unstable angina in the last 8 weeks
Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 8 weeks. NOTE: Any participant who experiences unstable or life-threatening cardiac disease during the run-in period will be excluded but can be rescreened 8 weeks after the resolution of the event.
Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 8 weeks prior to Visit 1
Any life-threatening condition, including malignancy, with a life expectancy \< 5 years, other than CV disease or COPD, that might prevent the participant from completing the study.
Use of maintenance ICS treatment within the past 12 months.
Unable to abstain from protocol-defined prohibited medications
Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer prior to Visit 1 (any other investigational product that is not identified in protocol is prohibited for use during the duration of the study).
Participants with a known hypersensitivity to LAMA, LABA or ICS or any component of the MDI.
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Previous randomization in the present study.
For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Athens?

Yes, this clinical trial (NCT06283966) has an active research site in Athens, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

COPD Treatment Options in Athens, AL

If you're searching for copd treatment options in Athens, AL, this clinical trial (NCT06283966) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Athens research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced copd specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all copd clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in Athens, AL

See all parkinsons disease clinical trials recruiting in Athens — not just this study.

Browse Parkinsons Disease Trials in Athens →

Browse More Trials by Condition

Parkinsons Disease TrialsCOPD TrialsAll Conditions →

Ready to Join in Athens?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Athens, AL